TLDR: Fangzhou Inc. (HKEX: 06086) has announced that its ‘XingJie’ Large Language Model (LLM) has successfully completed a crucial national generative AI service filing in China. This milestone, achieved at the first Guangdong Provincial LLM Filing Conference, positions Fangzhou to further advance its AI-driven chronic disease management solutions and expand its ‘AI+H2H’ (Hospital-to-Home) healthcare ecosystem, offering smarter and more personalized care.
SHENZHEN, China – November 2, 2025 – Fangzhou Inc. (HKEX: 06086), a prominent leader in AI-driven Internet healthcare solutions, has reached a significant regulatory milestone with the official completion of the National Generative AI Service Filing for its ‘XingJie’ Large Language Model (XJ LLM). The filing, designated as Guangdong-XingJie-202509120089, was confirmed by the Cyberspace Administration of China.
The announcement was made at the inaugural Guangdong Provincial LLM Filing Conference held in Shenzhen, where Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, emphasized the strategic importance of this achievement. “The successful launch of the ‘XingJie’ Large Language Model marks another milestone in Fangzhou’s advancement of AI-driven chronic disease management,” stated Dr. Xie. He further articulated the company’s vision: “Building on this momentum, we will continue to optimize our models and enrich our AI+H2H (Hospital-to-Home) healthcare ecosystem, integrating frontier AI capabilities with professional medical services so that every user can experience smarter, more accessible, and more personalized care support.”
This regulatory approval solidifies Fangzhou’s leadership in AI-powered chronic disease management, particularly following the earlier announcement of its ‘XingShi’ Large Language Model (XS LLM) in September 2025. The dual-model architecture of XJ LLM and XS LLM is set to transform chronic disease management from traditional, reactive approaches to a proactive paradigm centered on predictive insights and personalized interventions.
The XJ LLM serves as a foundational element within Fangzhou’s AI+H2H ecosystem, built upon three core pillars: technological advancement, application transformation, and operational efficiency. It integrates emotional perception and intent reasoning to anticipate user needs, orchestrating multiple models to deliver optimal service experiences. The ecosystem currently provides comprehensive, end-to-end intelligent services, including specialized programs for AI+weight management and AI+psoriasis care. These services encompass tailored medication guidance, disease education, targeted interventions, and continuous monitoring throughout the patient’s care journey.
Also Read:
- Cambodia Forges Ahead with AI and Data Security for Healthcare Transformation
- China Advocates for New Global AI Governance Body at APEC Summit
As of June 30, 2025, Fangzhou Inc. serves a substantial user base of 52.8 million registered individuals and collaborates with 229,000 physicians, underscoring its significant footprint in China’s online chronic disease management sector. The company remains dedicated to its mission of fostering ‘better health for all’ by leveraging cutting-edge technology to contribute to a healthier China.
